Department of Pathology Department Chair; Developmental Therapeutics Research interests: CNS metastasis, matrix metalloproteinases, and vascular targeting agents including combretastatin. Dr. Rojiani's research focusus on vascular changes and inflammation in Alzheimer's disease. 1120 15th Street BF 103 Augusta, GA 30912 Office: (706) 721-2923 E-mail: arojiani@georgiahealth.edu

Rojiani, Amyn, M.D., Ph.D.

Amyn Rojiani, MD, PhD

1120 15th Street
BF 103
Augusta, GA 30912
Office: (706) 721-2923
E-mail: arojiani@georgiahealth.edu
IFL Link | PubMed Link

Department of Pathology Department Chair; Developmental Therapeutics
Research interests: CNS metastasis, matrix metalloproteinases, and vascular targeting agents including combretastatin. Dr. Rojiani’s research focusus on vascular changes and inflammation in Alzheimer’s disease.

Education
M.D., University of Karachi, 1982
Ph.D., University of Medicine and Dentistry of New Jersey, 1987

Residency & Fellowships
Residency, University of Medicine and Dentistry of New Jersey, 1989 – Anatomic Pathology.

Fellowship, University of British Columbia/Vancouver General Hospital, 1991 – Neuropathology.

 Publications (selected)

Rice L, Pampo C, Lepler S, Rojiani AM, Siemann DW. Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503. Microvasc Res. 2011 Jan;81(1):44-51. Epub 2010 Oct 23. PubMed PMID: 20974154; PubMed Central PMCID: PMC3021177.

Rojiani AM: Matrix Metalloproteases and Their Inhibitors- Friend or Foe: in “The Tumor Microenvironment.” Editor: Siemann DW. Wiley and Sons. 2011

DeMers N, Rojiani AM, Brem S, Rojiani MV: Molecular Mechanisms of Metastasis to the CNS in “Mechanisms Of Carcinogenesis, Vol 2, Ed: D. Coppola; in the series Cancer Growth and Progression, 2nd Edition. 2011

Rojiani MV, Alidina J, Esposito N, Rojiani AM. Expression of MMP-2 correlates with increased angiogenesis in CNS metastasis of lung carcinoma. Int J Clin Exp Pathol. 2010 Oct 16;3(8):775-81. PubMed PMID: 21151391; PubMed Central PMCID: PMC2993228.

Riddle ND, Gorden L, Rojiani MV, Hakam A, Rojiani AM. CD44 and p53 immunoexpression patterns in NF1 neoplasms – indicators of malignancy and infiltration. Int J Clin Exp Pathol. 2010 Jun 12;3(5):515-21. PubMed PMID: 20606732; PubMed Central PMCID: PMC2897111.

Rojiani MV, Siemann DW, Rojiani AM. Cell proliferation index determination by immunohistochemical detection of hCDC47 protein. Appl Immunohistochem Mol Morphol. 2010 May;18(3):278-82. PubMed PMID: 20048674

Barami K, Sloan AE, Rojiani A, Schell MJ, Staller A, Brem S. Relationship of gliomas to the ventricular walls. J Clin Neurosci. 2009 Feb;16(2):195-201. Epub 2008 Dec 18. PubMed PMID: 19097905.

Chinnaiyan P, Wang M, Rojiani AM, Tofilon PJ, Chakravarti A, Ang KK, Zhang HZ, Hammond E, Curran W Jr, Mehta MP. The prognostic value of nestin expression in newly diagnosed glioblastoma: report from the Radiation Therapy Oncology Group. Radiat Oncol. 2008 Sep 25;3:32. PubMed PMID: 18817556; PubMed Central PMCID: PMC2563009.

Jain S, Houseknecht K, Rojiani AM, Setzer M, Vrionis FD. Management of nerve sheath tumors arising in the sympathetic chain. Cancer Control. 2008 Oct;15(4):352-7. PubMed PMID: 18813203.

Boeras DI, Granic A, Padmanabhan J, Crespo NC, Rojiani AM, Potter H. Alzheimer’s presenilin 1 causes chromosome missegregation and aneuploidy. Neurobiol Aging. 2008 Mar;29(3):319-28. Epub 2006 Dec 13. PubMed PMID: 17169464;PubMed Central PMCID: PMC2692942.

Sterns RH, Silver S, Kleinschmidt-DeMasters BK, Rojiani AM. Current perspectives in the management of hyponatremia: prevention of CPM. Expert Rev Neurother. 2007 Dec;7(12):1791-7. Review. PubMed PMID: 18052771.

Strickland-Marmol LB, Khoor A, Livingston SK, Rojiani A. Utility of tissue-specific transcription factors thyroid transcription factor 1 and Cdx2 in determining the primary site of metastatic adenocarcinomas to the brain. Arch Pathol Lab Med. 2007 Nov;131(11):1686-90. PubMed PMID: 17979487

Kharfan-Dabaja MA, Ayala E, Greene J, Rojiani A, Murtagh FR, Anasetti C. Two cases of progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation and a review of the literature. Bone Marrow Transplant. 2007 Jan;39(2):101-7. Epub 2006 Dec 4. Review. Erratum in: Bone Marrow Transplant. 2007 Feb;39(4):253-4. PubMed PMID: 17143300.

Rojiani MV and Rojiani AM: Morphologic Manifestations of Vascular Disrupting Agents in Pre-clinical Models.” In Vascular Targeting Agents in Oncology   Editor: Siemann DW. Wiley and Sons. 2006

Kleinschmidt-DeMasters BK, Filley CM, Rojiani AM. Overlapping features of extrapontine myelinolysis and acquired chronic (non-Wilsonian) hepatocerebral degeneration. Acta Neuropathol. 2006 Nov;112(5):605-16. Epub 2006 Jul 27. PubMed PMID: 16871403.

Silver SM, Schroeder BM, Sterns RH, Rojiani AM. Myoinositol administration improves survival and reduces myelinolysis after rapid correction of chronic hyponatremia in rats. J Neuropathol Exp Neurol. 2006 Jan;65(1):37-44. PubMed PMID: 16410747

Kleinschmidt-Demasters BK, Rojiani AM, Filley CM. Central and extrapontine myelinolysis: then…and now. J Neuropathol Exp Neurol. 2006 Jan;65(1):1-11.Review. PubMed PMID: 16410743.

Wang M, Tihan T, Rojiani AM, Bodhireddy SR, Prayson RA, Iacuone JJ, Alles AJ, Donahue DJ, Hessler RB, Kim JH, Haas M, Rosenblum MK, Burger PC. Monomorphous angiocentric glioma: a distinctive epileptogenic neoplasm with features of infiltrating astrocytoma and ependymoma. J Neuropathol Exp Neurol. 2005 Oct;64(10):875-81. PubMed PMID: 16215459

Morgan D, Gordon MN, Tan J, Wilcock D, Rojiani AM. Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics. J Neuropathol Exp Neurol. 2005 Sep;64(9):743-53. Review. PubMed PMID: 16141783.

Siemann DW, Rojiani AM. The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors. Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3): 846-53. PubMed PMID: 15936569

Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation. 2004 Dec 8;1(1):24. PubMed PMID: 15588287; PubMed Central PMCID: PMC539292.

Paris D, Townsend K, Quadros A, Humphrey J, Sun J, Brem S, Wotoczek-Obadia M, DelleDonne A, Patel N, Obregon DF, Crescentini R, Abdullah L, Coppola D, Rojiani AM, Crawford F, Sebti SM, Mullan M. Inhibition of angiogenesis by Abeta peptides. Angiogenesis. 2004;7(1):75-85. PubMed PMID: 15302999

Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, Wilson D, Wilson N, Freeman MJ, Gordon MN, Morgan D. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci. 2004 Jul 7;24(27):6144-51. PubMed PMID: 15240806.

Siemann DW, Rojiani AM. Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1512-7. PubMed PMID: 12459379

Siemann DW, Rojiani AM. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):164-71. PubMed PMID: 12007956.

Publications are updated quarterly. For a complete listing, see Dr. Rojianis’ work on PubMed.